In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Adaptor Proteins, Signal Transducing
/ antagonists & inhibitors
Adult
Animals
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
/ antagonists & inhibitors
Child
Female
Gene Silencing
Homeodomain Proteins
/ antagonists & inhibitors
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Mice
Myeloid Cell Leukemia Sequence 1 Protein
/ antagonists & inhibitors
Myeloid-Lymphoid Leukemia Protein
/ antagonists & inhibitors
Oncogene Proteins, Fusion
/ antagonists & inhibitors
Precision Medicine
/ methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Reverse Genetics
/ methods
Xenograft Model Antitumor Assays
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 09 2021
27 09 2021
Historique:
received:
18
06
2020
accepted:
09
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
24
10
2021
Statut:
epublish
Résumé
High-throughput sequencing describes multiple alterations in individual tumors, but their functional relevance is often unclear. Clinic-close, individualized molecular model systems are required for functional validation and to identify therapeutic targets of high significance for each patient. Here, we establish a Cre-ER
Identifiants
pubmed: 34580292
doi: 10.1038/s41467-021-25963-z
pii: 10.1038/s41467-021-25963-z
pmc: PMC8476619
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Antineoplastic Agents
0
Biomarkers, Tumor
0
DDIT4L protein, human
0
DUX4L1 protein, human
0
Homeodomain Proteins
0
MCL1 protein, human
0
MLL-AF4 fusion protein, human
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Oncogene Proteins, Fusion
0
Myeloid-Lymphoid Leukemia Protein
149025-06-9
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5655Informations de copyright
© 2021. The Author(s).
Références
Methods. 2017 Feb 15;115:80-90
pubmed: 27713081
Blood. 2005 Nov 15;106(10):3559-66
pubmed: 16046533
Haematologica. 2019 Aug;104(8):e352-e355
pubmed: 30705095
Biotechnol J. 2019 Mar;14(3):e1800219
pubmed: 29989353
Nat Rev Drug Discov. 2017 Aug;16(8):531-543
pubmed: 28685762
Leukemia. 2016 Nov;30(11):2152-2159
pubmed: 27479182
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Biol Chem. 2005 Mar 18;280(11):9769-72
pubmed: 15632201
Haematologica. 2018 Nov;103(11):e522-e526
pubmed: 29773604
EMBO J. 2019 Aug 1;38(15):e101654
pubmed: 31282586
Biomark Res. 2020 Sep 16;8:46
pubmed: 32944247
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30389682
Biochem Biophys Res Commun. 1997 Aug 28;237(3):752-7
pubmed: 9299439
Nucleic Acids Res. 1999 Nov 15;27(22):4324-7
pubmed: 10536138
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Ann Oncol. 2017 Oct 1;28(10):2595-2605
pubmed: 28945830
Haematologica. 2018 Mar;103(3):456-465
pubmed: 29242298
Anticancer Res. 2013 Dec;33(12):5273-87
pubmed: 24324060
Cancer Cell. 2020 Dec 14;38(6):872-890.e6
pubmed: 33217342
Onco Targets Ther. 2018 Oct 23;11:7301-7314
pubmed: 30425521
Neuron. 2018 Nov 21;100(4):783-797
pubmed: 30465765
Blood. 2019 Feb 7;133(6):566-575
pubmed: 30498064
Cancer Cell. 2016 Apr 11;29(4):574-586
pubmed: 27070704
Nat Genet. 2016 May;48(5):569-74
pubmed: 27019113
PLoS One. 2012;7(12):e52798
pubmed: 23300782
Nat Immunol. 2015 Apr;16(4):354-65
pubmed: 25729923
Am J Physiol Cell Physiol. 2009 Mar;296(3):C583-92
pubmed: 19129461
PLoS One. 2015 Mar 20;10(3):e0120925
pubmed: 25793878
Science. 2019 Sep 27;365(6460):1409-1413
pubmed: 31604268
BMC Biotechnol. 2003 May 22;3:5
pubmed: 12769828
Proc Natl Acad Sci U S A. 2019 Dec 9;:
pubmed: 31818951
Nat Biotechnol. 2017 Apr;35(4):350-353
pubmed: 28263295
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Blood. 2006 Jul 15;108(2):441-51
pubmed: 16556894
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13212-7
pubmed: 16141338
Gene Ther. 2011 May;18(5):479-87
pubmed: 21160533
Cell Rep. 2013 Dec 26;5(6):1704-13
pubmed: 24332856
FEBS Lett. 2001 Sep 21;505(3):467-73
pubmed: 11576551
Cancer Res. 2016 Aug 15;76(16):4619-26
pubmed: 27325646
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007870
Blood. 2016 Sep 8;128(10):1382-95
pubmed: 27343252
Cells. 2019 May 06;8(5):
pubmed: 31064068
PLoS One. 2016 Feb 10;11(2):e0147215
pubmed: 26863229
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Nat Biotechnol. 2014 Jan;32(1):40-51
pubmed: 24406927
Sci Signal. 2017 Feb 28;10(468):
pubmed: 28246202
Haematologica. 2020 Feb 06;105(12):2855-2860
pubmed: 33256387
Nat Genet. 2019 Feb;51(2):296-307
pubmed: 30643249
Cancer Cell. 2016 Dec 12;30(6):849-862
pubmed: 27916615
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Blood. 2010 Apr 8;115(14):2835-44
pubmed: 20032505
Pharmacol Ther. 2019 Jun;198:59-67
pubmed: 30790641
Nat Cancer. 2020 Mar;1(3):359-369
pubmed: 33345196
Leukemia. 2019 Apr;33(4):905-917
pubmed: 30214012
Nat Protoc. 2012 Feb 02;7(2):374-93
pubmed: 22301776
Nat Methods. 2011 Dec 04;9(1):81-3
pubmed: 22138822
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
Front Oncol. 2018 Aug 28;8:340
pubmed: 30211119
Blood. 2010 Dec 2;116(23):4874-84
pubmed: 20699438
Nat Biotechnol. 2003 May;21(5):562-5
pubmed: 12665802
Gigascience. 2018 Jun 1;7(6):
pubmed: 29846586
Cancer Res. 2020 Jun 1;80(11):2286-2297
pubmed: 32152150